According to the biodistribution characteristics of TGFβ in vivo and the solid tumor-penetrating property of TGFβ-targeting carrier drugs in existing research reports (14, 24, 25, 27), development of radionuclide-labeled targeting small-molecule or peptide inhibitors for imaging diagnostic application can be carried out, with potential indications including hematological tumors such as lymphoma, glioblastoma, sarcoma, pancreatic adenocarcinoma, lung squamous cell carcinoma, hepatocellular carcinoma, renal cell carcinoma, breast cancer, colorectal cancer, and urinary system cancers. This evidence concerns the gene TGFB1 and glioblastoma.